ArticleFrontiers in plant science2025
Engineering and application of multiepitope recombinant proteins to enhance resistance to
Article in Frontiers in plant science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Secreted proteins fromFrontiers in plant science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plant elicitors have emerged as key agents in effectively invoking immune responses across various plant species, gaining attention for their role in sustainable agricultural protection strategies. However, the economic utility of peptide elicitors such as flg22, flgII-28, and systemin is limited when considering broader agricultural applications. This study introduces a novel recombinant protein, SlRP5, which integrates five active epitopes-flg22, csp22, flgII-28, SIPIP1, and systemin-to activate immune responses and significantly enhance resistance to
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.